TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Peijia Medical Ltd. ( (HK:9996) ) has shared an update.
Peijia Medical Ltd. announced the successful enrollment of the first patient in a multi-center registration clinical trial for its ReachTactile™ robotic-assisted TAVR system. This trial aims to evaluate the safety and efficacy of the system, which features a mobile, modular design and real-time tactile feedback for precise navigation in complex vascular conditions. The outcome of this trial will support the company’s future registration application with the National Medical Products Administration, potentially enhancing its market position in the medical technology industry.
The most recent analyst rating on (HK:9996) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
More about Peijia Medical Ltd.
Peijia Medical Ltd. operates in the medical technology industry, focusing on the development of innovative medical devices. The company specializes in robotic-assisted systems for transcatheter aortic valve replacement (TAVR) procedures, aiming to provide cost-effective solutions for cardiovascular treatments.
Average Trading Volume: 2,370,892
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.22B
Learn more about 9996 stock on TipRanks’ Stock Analysis page.